Figure 3
The effects of inhibitors on proliferation, apoptosis, stemness, invasion and metastasis of miPS-CSC models in vitro. (a) The proliferation of miPS-CSC models after treated with Eganelisib and Gefitinib was measured by MTT assay. (b) The number of spheres with a diameter greater than 75 μm after miPS-CSC models treated with Eganelisib and Gefitinib for 48 h. The data were presented as the number of defined mammospheres per 2000 seeded cells. Representative bright field images for spheres were shown for each group. Scale bar: 100 μm. (c) miPS-CSC models were subjected to migration and invasion assays after treated with Eganelisib and Gefitinib, 100X. Mean ± s.d. for three independent replicates. (d) The apoptosis was analyzed by flow cytometry assay after treated with Eganelisib and Gefitinib. The concentration of Gefitinib we used was 11.0 μM in miPS-LLCcm, 6.5 μM in miPS-PK8cm, 34.7 μM in miPS-T47Dcm for 48 h. The concentration of Eganelisib we used was 14.6 μM in miPS-LLCcm, 18.1 μM in miPS-PK8cm, 16.38 μM in miPS-T47Dcm for 48 h for (b), (c) and (d). The cell was miPS-LLCcm in (b) and (c). *P < 0.05, ***P < 0.001, Tukey’s multiple comparisons test for (b) and (c).
